Category Archives: AZBio News

Rare Disease Cures Accelerator-Data and Analytics Platform First Year Milestones Highlighted at Virtual Workshop

Posted on by

C-Path, NORD, FDA and more come together to showcase the importance of data sharing in rare disease drug development

TUCSON, Ariz. and WASHINGTON, D.C. October 21, 2020 — The Critical Path Institute (C-Path) and the National Organization for Rare Disorders (NORD®) hosted the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP) 2020 Virtual Workshop on Monday, October 19. The platform, funded by a cooperative agreement through the U.S. Food and Drug Administration (FDA), serves as a centralized and standardized infrastructure to support data sharing and data analysis to aid in the understanding of rare diseases.Continue reading→

Calviri, Inc. Receives Exclusive Patent License to Immunosignature Technology, Strengthening Its Disease Diagnostic Capabilities

Posted on by

Calviri, Inc., a biotech startup focused on ending deaths from cancer, announces that Skysong Innovations, the intellectual property management company for Arizona State University (“ASU”), granted Calviri an exclusive license to ASU’s Immunosignature patent portfolio. The portfolio consists of multiple granted and pending patents for the use and optimization of immunosignatures as an antibody-based diagnostic platform in the United States and the rest of the world.Continue reading→

NIH begins large clinical trial to test immune modulators for treatment of COVID-19

Posted on by

The National Institutes of Health has launched an adaptive Phase 3 clinical trial to evaluate the safety and efficacy of three immune modulator drugs in hospitalized adults with COVID-19. Some COVID-19 patients experience an immune response in which the immune system unleashes excessive amounts of proteins that trigger inflammation — called a “cytokine storm” — that can lead to acute respiratory distress syndrome, multiple organ failure and other life-threatening complications. The clinical trial aims to determine if modulating that immune response can reduce the need for ventilators and shorten hospital stays. The trial, known as ACTIV-1 Immune Modulators (IM), will determine if the therapeutics are able to restore balance to an overactive immune system.Continue reading→